News

Under the terms of the agreement, Galapagos will pay Enceladus an upfront fee and run the clinical development of Nanocort. Enceladus will receive a minority share of future

Tony Piscopio, chairman and CEO of Optomagic, said: “We are pleased that Takeda has decided to further expand its partnership with Chemizon. With our recently announced strategic partnership

This approval is claimed to be the first for Humira in Japan, where Abbott co-developed and will co-market Humira with Eisai. Humira is expected to become available to

Under the terms of the agreement, Codon will receive clinical milestone payments and royalties on net sales that may result from Merrimack’s development and commercialization of any protein

Ofloxacin ophthalmic solution is an anti-infective used to treat infections caused by bacteria in conjunctivitis and corneal ulcers. Arthur Przybyl, Akorn’s president and CEO, said: “This product will

The company anticipates that this investment will create more than 100 new jobs in Massachusetts. The investment will support the construction of a center of excellence in discovery,

The results showed that 73% of patients who began the study on FTY720 (fingolimod) 5mg remained free from relapses after three years, and 68% of those who began

All patients vaccinated with CDX-110 in the Phase IIa ACT II extension study showed a tumor-specific immune response, a significant improvement over previous vaccines and over CDX-110 alone.

These results suggest that inhibiting the Hedgehog pathway with IPI-926, the company’s novel, potent Hedgehog pathway antagonist following chemotherapy delays tumor recurrence in small cell lung cancer (SCLC).